Background Remimazolam's role in pediatric anesthesia is evolving. We systematically reviewed 2024–2025 evidence to establish a clinical decision-making framework for its use. Methods Following PRISMA guidelines, a systematic search identified 23 studies (15 RCTs) involving 2, 847 pediatric patients for narrative synthesis. Results Remimazolam demonstrated superior hemodynamic stability vs. propofol (cardiovascular complications: RR 0. 30, 95% CI 0. 20–0. 46) and reduced emergence delirium by 61% (RR 0. 39, 95% CI 0. 21–0. 70). The CES1 G143E polymorphism was identified as a genetic basis for prolonged sedation, reducing drug clearance 90%. Critical limitations include a 15% re-sedation rate post-flumazenil, a complete lack of data in infants 1 year, and unknown long-term neurodevelopmental safety. Conclusion Remimazolam represents a valuable anesthetic tool with specific advantages in pediatric anesthesia. While it demonstrates superior hemodynamic stability and reduced emergence delirium compared to standard agents, it is not a universal replacement for established anesthetics. Current evidence supports its use in specific clinical scenarios, particularly for preventing post-sevoflurane emergence delirium and in hemodynamically unstable patients. However, the absence of infant and long-term neurodevelopmental safety data necessitates continued research before widespread adoption. Systematic Review Registration https: //www. crd. york. ac. uk/prospero/displayᵣecord. php? ID=CRD420251058023, PROSPERO CRD420251058023.
Zhang et al. (2025) studied this question.